Potential Utility of Retinal Imaging for Alzheimer’s Disease: A Review

Huan Liao¹,²*, Zhuoting Zhu³*, and Ying Peng¹,²*

¹ Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, ² Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, ³ State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China

The ensuing upward shift in demographic distribution due to the increase in life expectancy has resulted in a rising prevalence of Alzheimer’s disease (AD). The heavy public burden of AD, along with the urgent to prevent and treat the disease before the irreversible damage to the brain, calls for a sensitive and specific screening technology to identify high-risk individuals before cognitive symptoms arise. Even though current modalities, such as positron emission tomography (PET) and cerebrospinal fluid (CSF) biomarker, showed their potential clinical uses in early detection of AD, the high cost, narrow isotope availability of PET probes and invasive characteristics of CSF biomarker limited their broad utility. Therefore, additional tools for detection of AD are needed. As a projection of the central nervous system (CNS), the retina has been described as a “window to the brain” and a novel marker for AD. Low cost, easy accessibility and non-invasive features make retina tests suitable for large-scale population screening and investigations of preclinical AD. Furthermore, a number of novel approaches in retina imaging, such as optical coherence tomography (OCT), have been developed and made it possible to visualize changes in the retina at a very fine resolution. In this review, we outline the background for AD to accelerate the adoption of retina imaging for the diagnosis and management of AD in clinical practice. Then, we focus on recent findings on the application of retina imaging to investigate AD and provide suggestions for future research directions.

Keywords: Alzheimer’s disease, retinal imaging, early detection, novel biomarker, review

INTRODUCTION

Life expectancy has increased substantially during past few decades, mainly attributable to advancements of health care and lifestyle. The ensuing upward shift in demographic distribution has resulted in a rising prevalence of aging-related diseases, such as dementia. According to the report in Prince et al. (2015), dementia affects approximately 46.8 million people worldwide. AD,
as the most prevalent type of senile dementia by far, accounts for 60–80% of all cases with dementia (Prince et al., 2015). The prevalence of AD is estimated to quadruple and intensive health care will be needed for 43% of these patients by 2050 (Brookmeyer et al., 2007).

Despite of the heavy public disease burden of AD, there is no effective treatment for AD. Advances in the effective treatment and prevention of AD have been hampered by challenges in diagnosing the disease at the preclinical phase, in which subjects are still asymptomatic in clinical settings but may have subtle evidence of early cognitive deficits in the context of neuropathology specific to AD (Sperling et al., 2011a). Currently, diagnosis was primarily based on cognitive assessments among patients with symptomatic cognitive and behavior deficits (Dubois et al., 2014). Studies suggested that measurable changes in PET, MRI and CSF biomarkers occurred predates the onset of clinical symptoms (Beckett et al., 2010). Unfortunately, these are costly and/or invasive procedures that are not appropriate for screening at a population level.

As a projection of the CNS via the optic nerve, the retina has been described as a “window to the brain” and investigated intensively the potential of serving as a marker for AD (Guo et al., 2010; MacCormick et al., 2015). Low cost, easy accessibility and non-invasive features make retina tests suitable for large-scale population screening and investigations of preclinical AD. Furthermore, a number of novel approaches in retina imaging, such as OCT, have been developed and made it possible to visualize lesions and changes of the retina at a very fine resolution.

In this review, we outline the background for AD to accelerate the adoption of retina imaging for the diagnosis and management of AD in clinical practice. Then, we focus on recent findings on the application of retina imaging to investigate AD and provide suggestions for future research directions.

**CHALLENGES FOR EARLY DETECTION OF AD**

In 1906, Alois Alzheimer was credited with identifying the first condition of dementia, which was later to carry his name as AD. AD is a progressive neurodegenerative disease, in which synaptic and neuronal loss (Terry et al., 1987; Polanco et al., 2018) lead to irreversible deterioration in memory loss, cognitive impairment and behavioral deficits (Ghiso et al., 2013). Well-known pathological hallmark related to AD is the propensity of proteins to form toxic oligomers and fibrils (Jahn et al., 2010). The two key proteins related to AD are Aβ peptide and hyper-phosphorylated tau (Masters et al., 1985; Grundke-Iqbal et al., 1986). Aβ peptide is a small peptide derived from its parent molecule, the amyloid-β precursor protein (AβPP), and accumulates of Aβ into extracellular amyloid senile plaques (Polanco et al., 2018). Hyper-phosphorylated tau is a MAP that accumulates intraneuronally to form neurofibrillary tangles (Moore et al., 2016). Consistent evidences have demonstrated that neuropathological changes, mainly the accumulation of Aβ and tau, predate the emergence of clinical symptoms by as long as 15–20 years, emphasizing the potential of developing methods for early diagnosis (Holtzman et al., 2011).

According to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association criteria (McKhann et al., 1984), the first definition for diagnosis of AD is relied on neuropathological analysis of brain tissue, obtained by biopsy or autopsy, for the accumulation of Aβ peptides and tau protein. In the following decades, advances in the early diagnosis of AD have been hampered by challenges in differentiating earliest stage of AD with age-related cognitive deficit and other forms of dementia. Furthermore, AD is currently diagnosed by cognitive assessments among patients with symptomatic cognitive and behavior deficits (Dubois et al., 2014), which is usually the advanced stage and irreversible to treatment. Despite of enormous financial and scientific efforts, the treatment of AD has remained symptom-driven and no single disease-modifying therapy for AD has been approved. So far, it has been documented the high failure rate – nearly 90% – of clinical drug trials for AD. One of possible reasons for the high failure rate might be the inclusion of patients with the uncertainty diagnosis and/or late-stage disease (Sperling et al., 2011b; James et al., 2015; Jellinger and Attems, 2015). Two phase 3 clinical trials (Doody et al., 2014; Salloway et al., 2014) investigated the anti-Aβ antibody’s effect on the treatment of mild-to-moderate AD. Neither study showed a significant benefit of solanezumab (Doody et al., 2014) or bapineuzumab (Salloway et al., 2014) for primarily designated outcomes. However, with sub-analysis of participants with mild AD, half of the prespecified endpoints was met and cognitive deficits were slowed by 34% (Siemers et al., 2016), suggesting the therapy may be effective in treating the early course of AD. A recent phase 1b randomized trial of monthly intravenous infusion of the anti-Aβ antibody abcanumab in patients with prodromal or mild AD did not have enough power to detect clinical change, however, post hoc analysis suggested the reduction of Aβ burden in brain and a stabilization of cognitive decline based on Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores (Sevigny et al., 2016). Modeling has suggested that interventions aimed at clearing Aβ accumulation may be sufficient to delay the onset of clinically manifest AD, reduce the incidence and the progression of AD if started in the early stages of AD (Brookmeyer et al., 1998). These findings again stress the importance of early detection of AD.

The increasing global prevalence of AD, along with the urgent to prevent and treat the disease before the irreversible damage to the brain, calls for a sensitive and specific screening strategy to identify individuals at high risk of AD before cognitive symptoms arise. A large number of novel methods for diagnosis of AD have been developed during the past decades. Non-invasive neuroimaging tools such as MRI can detect subclinical structural brain changes (e.g., atrophy) related to the future risk of AD. However, due to limited spatial resolution, MRI measures may not be able to detect subtle changes at the early stages. Although specific neuropathology biomarkers, such as the detection of Aβ and tau accumulation measured by PET imaging (James et al., 2015; Dubois et al., 2016) and in CSF...
The Retina – A “Window to AD”

As an extension of the CNS, the retina and optic nerve share many features in terms of embryological origin, anatomy, response to injury, immunology and physiological characteristics, with the brain (London et al., 2013). The retina and optic nerve originate from the diencephalon during embryonic development, and therefore are considered as an extension of the CNS. Photoreceptor cells of the retina capture light and initiate neuronal signals that eventually reach the RGCs. The optic nerve composed of the axons of RGCs passes the visual information to the higher visual processing centers in the brain. RGCs show the typical patterns of CNS neurons and comprise a cell body, dendrites and an axon. Similar to all fiber tracts of CNS, the optic nerve is myelinated as they leave the eyes. Insult to the optic nerve leads to degeneration of the axons, myelin damage and inducing a neurotoxic condition, which are also observed in other CNS axons (Faden and Salzman, 1992; Schwartz et al., 1996; Crowe et al., 1997; Yoles and Schwartz, 1998; Levkovitch-Verbin et al., 2001, 2003). After injury, similar limited regeneration environment exists in the retina, optic nerve and other CNS compartments. The eye and the brain normally maintain strict interactions with immune system, and both are immune-privileged organs. Furthermore, ocular inner BRB resembles the BBB strongly with respect to structures, characteristics and mechanisms (Kaur et al., 2008).

RETINAL CHANGES AND AD

Given these strong connections between the brain and the retina, it has been indicated that neurodegenerative disease, such as AD, may also lead to similar pathology in RGCs and optic nerve. The retina and brain are directly connected by axons of the optic nerve, which facilitate transportation of APP synthesized in RGCs in small transport vesicles (Morin et al., 1993). Furthermore, retinal neurons and glia express proteins that have participated in the amyloid cascade (e.g., BACE1, γ-secretase, APOE) (Cai et al., 2012; Li et al., 2016; Vecino et al., 2016). Several studies verified the presence of classical biomarkers of AD, Aβ and tau, within the retina and optic nerve at the molecular level (Gasparini et al., 2011; Koronyo-Hamaoui et al., 2011). Retinal Aβ deposits triggers breakdown of RPE tight junction (Park et al., 2014) and integrity of the blood-retina barrier (Dinet et al., 2012), increases reactive oxygen species production (Bruban et al., 2009), and activates complement by upregulating factor B (Wang et al., 2009). The crucial roles of Tau played in retina include regulating the cytoskeletal and axonal transport in retinal neurons, increasing Aβ accumulation and affecting cell survival signaling in the retina (Ho et al., 2012). Therefore, the toxic effects of these deposits include the apoptosis of the RGCs, thinning of the RNFL, morphological changes in the optic nerve, and other retinal structural and functional impairment of AD patients (Hinton et al., 1986; Tsai et al., 1991; Hedges et al., 1996; Danesh-Meyer et al., 2006; Iseri et al., 2006; Paquet et al., 2007; Ning et al., 2008; Perez et al., 2009; Parnell et al., 2012; Garcia-Martin et al., 2014; Saloabrar-Garcia et al., 2015). Studies using animal models of AD have demonstrated that AβPP and Aβ were accumulated in all six layers of the neuroretina (Liu et al., 2009), with the extent proportional to the increasing age of the animal models. Furthermore, animal models have shown that retinal senile plaques were correlated with plaque load in the brain (Koronyo et al., 2012) and were detected prior to the plaque deposition in the brain, implying that Aβ deposition seen in the retina could be an early related sign of AD detection (Zhang-Nunes et al., 2006; Koronyo-Hamaoui et al., 2011). In addition, hyperphosphorylated tau has been reported to accumulate in the RNFL of transgenic AD mouse models, which results in disruption of axonal transport and ganglion cell degeneration (Gasparini et al., 2011; Bull et al., 2012).

It has been suggested that AD might also be a disease of the neurovascular unit indicated from results of cerebral amyloid angiopathy, focal lesions in brain microcirculation system and strong associations between vascular changes of AD with typical neuronal degenerative changes (Zlokovic, 2011). The overproduction of Aβ in the retinal vascular increases the mechanical stress to endothelial cell regulation of AβPP, with associated destruction of the vessel walls, leading to changes of vascular diameters and topology (Golzan et al., 2017). A large body of evidences have also verified potential associations between AD and retinal vascular parameters, both static and dynamic, such as retinal vascular diameters, retinal pulsatility and local arterial PWV (Bernisha et al., 2007; Pase et al., 2012; Frost et al., 2013; Feke et al., 2015; Williams et al., 2015). Transgenic animal models of AD have shown Aβ and senile plaques accumulation in retinal vasculature (Zhang-Nunes et al., 2006; Liu et al., 2009).

IMAGING RETINA TO STUDY AD

The visualization of detailed structure and functions of the retina has dramatically improved with the development of modern imaging techniques. This has provided clinicians and
researchers with valuable tools for potential early diagnosis and differentiation, monitoring progression, and clinical drug trials of AD (Table 1).

**STRUCTURAL IMAGING METHODS**

**Ocular Fundus or Retinal Photography**

Ocular fundus or retinal photography is the classic imaging technique for investigating the retina, providing routine retinal checks in eye clinics. Ocular fundus or retinal photography is able to detect three types of retinal vascular signs: (1) qualitative retinopathy and retinal arteriolar signs, (2) changes in retinal vascular caliber and (3) changes in global geometrical patterns of the retina (Cheung et al., 2012a).

Large number of studies have documented that qualitative retinal vascular signs and quantitative vascular measures, including retinopathy, vascular reduction, increasing variability of vessel width, attenuate complexity of branching characteristic, reduced optimality of the branching geometry and less tortuous venules, are associated with poorer cognitive performance based on different neuropsychological tests (Patton et al., 2007; Liew et al., 2009; Ding et al., 2011; Kim et al., 2011; Cheung et al., 2012b; Gatto et al., 2012; Ong et al., 2014; Taylor et al., 2015). The Rotterdam Study found that retinopathy was associated with AD in a cross-sectional population-based sample of individuals aged 55 years and older, whereas longitudinal data from the same study showed no association with incident AD (Schrijvers et al., 2012). Retinopathy was not significantly associated with AD when investigated in the Cardiovascular Health Study (Baker et al., 2007) and the AGES-Reykjavik Study (Qiu et al., 2010). With respect to AMD, Williams et al. (2014) showed an association between the most advanced cases and AD, whereas the association was lost after adjustment for confounding variables. Similarly, Klaver et al. (1999) found that risk of AD increased for patients with advanced stage AMD after 25.2 months follow up. However, the association was not significant following adjustment for smoking and atherosclerosis. In terms of the morphology of the ONH, a significant correlation of the optic neuropathy with the onset, severity and duration of AD was confirmed previously (Tsai et al., 1991; Hedges et al., 1996). With CRAE as an index of vessel caliber, data from the three studies (Frost et al., 2013; Cheung et al., 2014; Williams et al., 2015) were pooled and indicated a reduction in arteriolar width in AD. Increasing standard deviation of microvascular widths and microvascular attenuation in AD were found using different measures of arteriolar and venular caliber (Frost et al., 2013; Cheung et al., 2014). Three case-control studies (Frost et al., 2013; Cheung et al., 2014; Williams et al., 2015) examined the link between retinal geometric branching parameters, such as fractal dimensions, branching patterns and tortuosity in AD patients. Findings from these studies reported consistent significant reduced venular, arteriolar, and total fractal dimensions, indicating a sparser network in AD (Figure 1). These studies have also consistently shown reduced complexity and optimality of the branching pattern. However, results of tortuosity were mixed when compared AD patients with control subjects. In addition, AD patients’ fundus images illustrated different patterns of RNFL abnormalities, including diffuse and wedge shape RNFL drop-out (Lu et al., 2010).

Current software programs for quantitative measurement of retinal vasculature in routine retinal image are not fully automated and therefore additional efforts are needed by technicians and clinicians. Novel software programs are being developed to fully automatically measure ocular fundus features such as calibers, tortuosity and network complexity, facilitating a more efficient assessment (Cheung and Wong, 2012; Nguyen et al., 2013; Joshi et al., 2014; Cavallari et al., 2015; Abramoff et al., 2016; Walton et al., 2016). In addition, with the advent of the non-mydriatic ultra-wide field retinal imaging technology, up to 200°, rather than the common 45° or 60°, of the retina can be captured in a single shot for investigating peripheral lesions (Kernt et al., 2012), which may provide a more comprehensive picture of the overall retinal vascular structure and retina (Cheung et al., 2010). A very recent pilot study using ultra-wide field retinal imaging identified peripheral biomarkers, including markedly increased drusen number, significant increase in venular width gradient and significant decrease in arterial fractal dimension, for AD and its progression over 2 years (Csincsik et al., 2018) (Figure 2).

It is noteworthy that the association between retinal changes with cognitive impairment and AD is weak and non-specific (Heringa et al., 2013), partly due to the nature variation of retinal vascular parameters and common retinal lesions shared by many diseases, which may limit the usage of a single ocular fundus photography screening test for AD. However, it is possible that longitudinal analysis of retinal changes might be a potential tool to accurately detect preclinical AD or monitor AD. Further longitudinal studies are thus needed to explore this possibility and determine time course of retinal changes in AD.

**Optical Coherence Tomography (OCT)**

Optical coherence tomography, a non-invasive technique providing high-resolution imaging of retina based on the principle of low coherence interferometry (Huang et al., 1991; Puliafito et al., 1995), has been extensively used to evaluate the morphological changes of the retina, such as peripapillary RNFL, macular thickness and volume, in AD. In line with the findings from post mortem studies, studies using OCT demonstrated a significant decline in peripapillary RNFL, and changes in macular thickness and volume in the eyes of patients that are progressive from MCI to AD. Results from two recent meta analysis (Coppola et al., 2015; Thomson et al., 2015) indicated that the attenuation in RNFL thickness, as observed in most studies, was significantly greater both in AD and MCI patients than that observed in the age-matched healthy controls. The mean RNFL thickness was confirmed to be reduced in AD and MCI patients in all quadrants (Paris et al., 2001; Iseri et al., 2006; Paquet et al., 2007; Kesler et al., 2011; Kang and Kim, 2013; Kirbas et al., 2013; Ascaso et al., 2014; Polo et al., 2014; Gunes et al., 2015), but some studies reported reduction of RNFL thickness predominantly in the superior (Paris et al., 2010).
| Techniques | Summary | Main findings | High lights | Limitation/Future Direction |
|------------|---------|---------------|-------------|----------------------------|
| Structural imaging techniques | Color photograph of retinal surface. | (a) Qualitative: retinopathy, optic neuropathy; (b) Retinal vascular caliber: vascular reduction, increasing variability of vessel width; (c) Global geometrical patterns: attenuation of complexity and optimality in the branching geometry; (d) Patterns of RNFL abnormalities: diffuse and wedge shape RNFL drop-out; (e) Increased drusen number, venular width gradient in peripheral retina; (f) Reduction in arterial fractal dimension in peripheral retina. | (a) Widely used; (b) Rapid; (c) Consistent; (d) Economic; (e) Non-invasive; (f) Novel fully automatically software programs: facilitating a more efficient assessment; (g) Non-mydriatic ultra-wide field retinal imaging technology: more comprehensive picture. | (a) Weak association; (b) Non-specific; (c) Longitudinal studies are needed; (d) Efficiency in measurement of retinal vasculature of ultra-wide field ocular fundus need to be established. |
| Ocular fundus | Near-infrared light penetrates retina; interferometry resolves tissue layers. | (a) RNFL thinning; (b) Ganglion cell complex atrophy; (c) Decline in macular thickness and volume; (d) Reduction in retinal total thickness; (e) Signs of optic neuropathy: optic disk atrophy, cupping, and attenuation of neuroretinal rim. | (a) Rapid; (b) Consistent; (c) Economic; (d) Non-invasive; (e) Image registration for precise follow-up imaging; (f) Eye tracking systems to reduce motion artifacts and noise. | (a) No visualization of single cell; (b) Susceptible to ocular opacity; (c) Poor comparability between different instrument; (d) Non-specific changes to AD. |
| Optical coherence tomography (OCT) | Confocal laser beam scans of retinal surface. | (a) Significant reduction in the RNFL; (b) Reduction in neuroretinal rim; (c) Increasing vertical cup-to-disk. | (a) Non-invasive; (b) Patient-friendly (less-bright light); (c) Larger field of view; (d) Reconstruction of three-dimensional structures; (e) Increasing resolution and contrast; (f) Differentiation among neurodegenerative diseases. | (a) Poor axial resolution; (b) No visualization of single cell; (c) Expensive. |
| Confocal scanning laser ophthalmoscopy (cSLO) | Real-time visualization of apoptotic retinal cells. | Detection of increasing number of apoptotic RGCs in AD animal models. | (a) Non-invasive; (b) Quantifiable; (c) Single-cell fluorescence resolution; (d) Assessment of treatment effectiveness; (e) Screening of new drugs. | (a) Healthy dataset of apoptotic cells needs to be established; (b) Efficiency in AD patients is needed. |
| Detection of Apoptotic Retinal Cells (DARC) | | | | |

(Continued)
| Techniques | Summary | Main findings | High lights | Limitation/Future Direction |
|------------|---------|---------------|-------------|-----------------------------|
| **Functional imaging techniques** | | | | |
| Pattern electroretinogram (PERG) | Using pattern-reversal stimuli and capturing retinal ganglion cell activity. | (a) Reduction in the amplitude of ERG responses; (b) Attenuation of the ERG signal. | Potential early detection of AD. | (a) Quite cumbersome; (b) Time-consuming. |
| Retinal oximetry | Spectrophotometric fundus imaging to measure oxygen saturation in retinal blood vessels. | Increasing arterial and venular oxygen saturation in MCI and moderate AD patients. | (a) Quick; (b) Safe; (c) Easily performed; (d) Patient-friendly; (e) Low variability; (f) High reproducibility. | (a) Pupil dilation is needed; (b) Sensitive to optical media opacities. |
| Doppler OCT | Visualization and quantification of blood flow in vivo. | (a) Significant reduction in the blood flow rate of the retina; (b) Narrowing retinal blood column. | (a) Rapid; (b) Consistent; (c) Economic; (d) Non-invasive; | (a) No visualization of single cell; (b) Susceptible to ocular opacity. |
| Retinal microperimetry | Topographic correlation between fundus details and light sensitivity of macular function. | Retinal sensitivity correlated with brain neurodegeneration among type 2 diabetes patients. | (a) Non-invasive; (b) Simple; (c) Fast; (d) Independent of the fixation and any other eye movement; (e) Independent of mood or depressive disorders; (f) High sensitivity; (g) Cost-effectiveness. | Micropenometry normative database in aging healthy controls and type 2 diabetic subjects without cognitive impairment is needed. |
| **Animal studies** | | | | |
| Multiphoton microscopy | Near-infrared light emitted by fluorescent dyes of A01-987 and ORANAD-2. | Detection of cerebral Aβ plaques in animal models. | (a) High specificity; (b) Suitability for PET scan. | (a) Highly invasive; (b) Restricted fluorescent signal. |
| Micron retinal imaging microscope | Visualization of fluorescence signals at high resolution and equipped with a 3-CCD camera, and specific set of filters suitable to detect curcumin fluorescence. | Dynamic pattern of plaque formation and clearance following immunotherapy. | (a) Real-time; (b) High-resolution; (c) Efficient; (d) Low-cost; (e) Easy operation. | Humans studies are needed. |
Recent studies using early AD and MCI (Gharbiya et al., 2014; Bayhan et al., 2015) have reported changes of specific retinal layers at the macular region in AD and supported the macular GC-IPL thinning being a new marker for detection of neurodegenerative damage in early AD and MCI (Gharbiya et al., 2014; Bayhan et al., 2015; Cheung et al., 2015; Gao et al., 2015). Two recent studies using the improved OCT indicated significant reductions in macular GCC in AD patients than the age-matched healthy controls (Marziani et al., 2013; Bayhan et al., 2015). When compared to patients with peripherpillary RNFL axonal loss, patients with MCI were more specifically present with reduced macular GC-IPL (Cheung et al., 2015). The first prospective and longitudinal study found the attenuation of macular RNFL might be the earliest anatomic marker of retinal neuronal loss in the preclinical stage of AD and such loss accounted for approximate 10% of the variance in neocortical amyloidosis observed by PET imaging (Santos et al., 2018).

Limitations of these technologies should be noted when interpreting the potential utility of OCT in AD management. First, ocular opacity, such as cataract, has profound impacts on the quality of the imaging. However, newer imaging methods, such as Swept source (SS)-OCT, could overcome this limiting factor, since SS-OCT offers additional advantages over SD-OCT in penetration depth and therefore reduced sensitivity to ocular opacity (Esmaeelpour et al., 2010). Second, instrument variability and different protocols in studies may hinder the comparability between different studies. It should be noted that meta analysis of the different commercial OCT results might be offset to statistical differences in the retinal structural changes. Therefore, standardized OCT protocol to study AD is needed in the near future. Third, structural changes in retina observed in AD patients may be non-specific to AD and shared by other ocular diseases, such as decreased RNFL in glaucoma. Nevertheless, combination OCT measurements of structural changes in retina and other biomarkers could potentially be a valuable approach in AD diagnosis and prognostication.
FIGURE 3 | Example of peripapillary retinal nerve fiber layer (RNFL) thickness OCT measurements taken from the right eye of: a healthy control with all quadrants with (A) thickness normal for age, (B) a MCI patient with a decreased RNFL thickness in the temporal quadrant, and (C) a AD patient with decreased RNFL thickness in all quadrants. The line of graphic shows the RNFL thickness of the scanning circle as seen around the optic nerve head in the picture on the right. The colors represent normal distribution percentiles for age. Green: 95-5%; yellow: 5-1%; red: 1-0% (Ascaso et al., 2014).

Confocal Scanning Laser Ophthalmoscopy (cSLO)

Confocal scanning laser ophthalmoscopy is an imaging technique and allows for reconstructing three-dimensional structures with advantages of increasing resolution and contrast. Morphological changes in the ONH measured by cSLO, including a significant reduction in the RNFL, neuroretinal rim, and increased vertical cup-to-disk, were found in AD patients in comparison to healthy subjects (Danesh-Meyer et al., 2006). In contrast to this finding, a recent study using cSLO did not document significant difference in the ONH between AD patients and healthy controls (Kurna et al., 2014). However, AD patients could be differentiated from glaucoma patients, implying the potential utility of cSLO as a new biomarker to recognize specific neurodegenerative diseases (Kurna et al., 2014). Using a lipid curcumin fluorochrome and a modified point cSLO, a recent study reported the increased burden of retinal amyloid deposits in live AD patients, which might lead to a practical approach for large-scale AD screening and monitoring (Koronyo et al., 2017).

Detection of Apoptotic Retinal Cells (DARC)

Detection of apoptotic retinal cells is a novel imaging technology that can monitor RGC apoptosis. Although RGCs can not be real-time visualized without a marker, it has been indicated that DARC is a useful tool to detect RGC apoptosis in vivo in experimental animal models (Cordeiro et al., 2004, 2010; Guo et al., 2006, 2007; Maass et al., 2007) (Figure 4). Combined with fluorescein labeled annexin V and a cSLO, DARC allows for visualization of single RGCs undergoing apoptosis. Using DARC imaging, the number of apoptotic RGCs in a AD model significantly increased, which became even worse under oxidative
stress when compared to healthy controls (Cordeiro et al., 2010). Furthermore, intraocular administration of extraneous Aβ peptides can lead to considerable RGC apoptosis *in vivo*, which can be treated and reserved by drugs targeting Aβ pathway (Guo et al., 2007). This finding promises the potential of assessing treatment effectiveness and screening new drugs by the means of DARC (Guo et al., 2006, 2007, 2014; Salt et al., 2014). Accordingly, although there is no study investigating the efficacy of DARC in patients with AD, a Phase I clinical trial of using DARC (ISRCTN59484478) in healthy and glaucoma subjects has recently been completed and DARC is believed to be used as a valuable tool in early diagnosis and treatment assessment for AD.

**FUNCTIONAL IMAGING METHODS**

**Pattern Electroretinogram (PERG)**

Pattern electroretinogram allows to objectively assess ganglion cells and their axons’ electrical response to patterned stimuli (Mafei and Fiorentini, 1981; Katz et al., 1989; Trick et al., 1989). Several studies have consistently reported abnormal PERG in AD patients, such as a significant reduction in the amplitude of ERG responses and an attenuation of the ERG signal (Katz et al., 1989; Trick et al., 1989; Parisi et al., 2001), further suggesting the evidence of retinal ganglion cell dysfunction related to the structural changes in the RNFL of AD patients (Parisi et al., 2001; Parisi, 2003). However, conflicting results were also demonstrated in other studies revealing normal ERG responses in mild to moderate AD (Strenn et al., 1991; Kergoat et al., 2002). Nevertheless, PERG can be useful in early phase of the AD, when RGC dysfunction and optic nerve alteration are already existed (Krasodomska et al., 2010) (Figure 5). However, PERG is quite cumbersome and time-consuming, which may limit its broad availability and utility.

**Retinal Oximetry**

Retinal oximetry is a spectrophotometric fundus imaging to measure oxygen saturation in retinal blood vessels in a non-invasive, fast and safe manner (Jani et al., 2014). Retinal oximetry can reliably and repeatedly detect changes in oxygen metabolism to reflect metabolic and functional changes in retina (Yip et al., 2014). Due to the availability of the retinal oximetry to clinical researchers in the past decade, retinal oximetry has offered new insights into several retinal diseases, such as diabetic retinopathy, glaucoma, as well as diseases of the brain, including AD (Stefansson et al., 2017). Einarsson et al. (2016) were the first to report oximetry abnormalities in retinas of AD patients compared with a healthy cohort. These findings have recently been confirmed and extended to patients with MCI (Olafsdottir et al., 2018) (Figure 6). Further studies are needed to confirm and expand the utility of retinal oximetry in AD clinical practice and trials.

**Doppler OCT**

As one of the functional extensions of OCT, Doppler OCT aims to visualize and quantify blood flow *in vivo*. Significant reduction in the blood flow rate of the retina and narrowing retinal blood column had been identified through Doppler OCT in patients with AD when compared with control subjects (Berisha et al., 2007), verifying the potential association between changes of blood flow in the retina and the brain. The decreased perfusion both in the retina and the brain may affect ATP synthesis...
and cause oxidative stress, which resulted in neuronal death (Ruitenberg et al., 2005). Doppler OCT has been shown the potential to improve the ability to diagnose and monitor AD through ocular vascular changes.

**Retinal Microperimetry**

Retinal microperimetry is a simple, non-invasive and fast test that measures the topographic correlation between fundus details and light sensitivity for macular function (Rohrschneider et al., 2008; Acton and Greenstein, 2013) (Figure 7). Independent of the fixation and any other eye movement, retinal microperimetry is a strong candidate examination for monitoring AD. It has been indicated that retinal sensitivity evaluated by retinal microperimetry correlated with brain neurodegeneration and could be a novel biomarker for predicting the risk of developing AD among type 2 diabetes patients (Ciudin et al., 2017). Some recent studies have documented more sensitivity of microperimetry in identifying early functional changes of the retina than ERG (Wu et al., 2014). Therefore, retinal microperimetry might be a cost effective way of managing the diagnosis and progression of AD in the future.

**STUDIES IN ANIMAL MODELS**

Some of the promising retinal imaging technologies have been applied and tested in animal models. In a mice model expressing human mutant P301S tau, aggregation and progression of fibrillar tau in the retina were detected by cSLO over several months (Schon et al., 2012). This technique may be suitable to manage therapeutic interventions aimed at reducing fibrillar tau aggregation in the retina. Using fluorescent dyes AO1-987 and CRANAD-2 which can emit near-infrared light, multiphoton microscopy has been used to detect cerebral Aβ plaques in AD animal models (Hintersteiner et al., 2005). Despite of high specificity and suitability in PET scan (Ran et al., 2009), this technique is highly invasive and a cranial window is needed (Dong et al., 2010). Moreover, fluorescent signal is limited on the cortical surface (Meyer-Luehmann et al., 2008). Micron II retinal imaging microscope was used in vivo to document dynamic pattern of plaque formation and clearance following immunotherapy (Koronyo et al., 2017). This technology may be a useful tool to monitor progression and assess therapy efficiency in AD patients.

**FUTURE DIRECTIONS**

Even though the current findings and applications of retinal imaging in AD patients offer a promising future, however, there are still several gaps to be filled in the future research. First, the underlying mechanisms between retinal changes and AD have not been completely elucidated, which may hinder the translation of retinal imaging into a valuable tool in AD clinical
practice. Future experimental research that explores the etiology of AD and biological mechanism between retinal changes and AD is needed to facilitate the utility of retinal imaging in AD patients. Second, studies with large sample size and long-term follow-up are needed to clarify longitudinal retinal changes and its relation to AD, thus building prediction models to identify the patients at risk of developing AD. Third, a large number of novel retinal imaging technologies have been used to estimate the structure and functions of the retina, such as OCT-angiography, and retinal function imager. Very recent work has used OCT-angiography in AD patients and provided promising results that significant decreased retinal vascular density and enlarged foveal avascular zone were observed in AD group compared with the control group (Bulut et al., 2018). Further studies are needed to confirm the utility and assess the cost-effectiveness of such newer technologies in AD monitoring. Furthermore, the diagnostic and prognostic values of combining different retinal imaging technologies with neurological examinations should be investigated for the further development of multimodal for clinical use. Finally, inclusion of different types of dementia, such as Lewy body dementia, to the clinical trial is important to clarify the specific clinical implications of retinal imaging technologies in AD patients. In addition, some neurodegenerative brain disorders, such as Parkinson's disease, have also shown morphological evidence of disruption of retinal structure and function (Archibald et al., 2009). Understanding neurodegeneration in the retina may provide not only a clearer picture of brain disorders' onset and progression, but also promising non-invasive tools for large-scale screening and monitoring brain diseases.

**CONCLUSION**

Structural and functional retinal changes have been suggested as the window to the neurodegenerative diseases. Retinal imaging is a non-invasive, cost-effective and highly promising method to study AD and provides new and additional important insights...
into AD. Future studies investigating underlying mechanisms between retinal changes and AD and the utility of combining retinal imaging technologies with neurological examinations are needed before retina imaging can be translated as a useful tool in clinical practice.

AUTHOR CONTRIBUTIONS
HL, ZZ, and YP conceived of the idea for the study. HL and ZZ searched and reviewed literature, drafted and revised the manuscript. YP reviewed and edited the manuscript. All authors read and approved the final manuscript.

FUNDING
This work was supported by the Key Project of Product, Study and Research of Guangzhou city (No. 201508020058) to YP, the International Collaboration Program of Universities in Guangdong Province (No. 2012gjhz001) to YP.

REFERENCES
Abramoff, M. D., Lou, Y., Erginay, A., Clarida, W., Amelon, R., Folk, J. C., et al. (2016). Improved automated detection of diabetic retinopathy on a publicly available dataset through integration of deep learning. Invest. Ophthalmol. Vis. Sci. 57, 5200–5206. doi: 10.1167/iovs.16-19964
Acton, J. H., and Greenstein, V. C. (2013). Fundus-driven perimetry (microperimetry) compared to conventional static automated perimetry: similarities, differences, and clinical applications. Curr. J. Ophthalmol. 48, 358–363. doi: 10.1016/j.jocjo.2013.03.021
Archibald, N. K., Clarke, M. P., Mosimann, U. P., and Burn, D. J. (2009). The retina in Parkinson’s disease. Brain 132(Pt 5), 1128–1145. doi: 10.1093/brain/awp068
Asgasco, F. J., Cruz, N., Modrego, P. J., Lopez-Anton, R., Santabarbara, J., Pascual, L. F., et al. (2014). Retinal alterations in mild cognitive impairment and Alzheimer's disease: an optical coherence tomography study. J. Neurol. 261, 1522–1530. doi: 10.1007/s00415-014-7374-z
Baker, M. L., Marino Larsen, E. K., Kuller, L. H., Klein, R., Klein, B. E., et al. (2010). Retinal microvascular signs, cognitive function, and dementia in older persons: the Cardiovascular Health Study. Stroke 38, 2041–2047. doi: 10.1161/STROKEAHA.107.483586
Bateman, R. J., Xiong, C., Benzing, T. L., Fagan, A. M., Goate, A., Fox, N. C., et al. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795–804. doi: 10.1056/NEJMa1202753
Bayhan, H. A., Aslan Bayhan, S., Celikbilek, A., Tanik, N., and Gurdal, C. (2015). Evaluation of the chorioretinal thickness changes in Alzheimer’s disease using spectral-domain optical coherence tomography. Clin. Exp. Ophthalmol. 43, 145–151. doi: 10.1111/ceo.12386
Beckett, L. A., Harvey, D. J., Gamst, A., Donohue, M., Kornak, J., Zhang, H., et al. (2010). The Alzheimer’s disease neuroimaging initiative: annual change in biomarkers and clinical outcomes. Alzheimers Dement. 6, 257–264. doi: 10.1016/j.jalz.2010.03.002
Berisha, F., Feke, G. T., Trempe, C. L., McMeel, J. W., and Schepens, C. L. (2007). Real-time imaging of single nerve cell apoptosis in retinal monkeys. Cell Death Dis. 1073/pnas.0405479101
Brookmeyer, R., Gray, S., and Kawas, C. (1998). Projections of Alzheimer’s disease: an optical coherence tomography study. J. Neurol. 245, 45–56. doi: 10.1155/2015/752957
Bulut, M., Kurtulus, F., Guzayka, O., Erol, M. K., Cengiz, A., Akidan, M., et al. (2018). Evaluation of optical coherence tomography angiographic findings in Alzheimer’s type dementia. Brain Aging Cell 133(Pt 7), 888, 1337–1342. doi: 10.2105/AJPH.2012.309814
Cai, J., Qi, X., Kociôk, N., Skosyrski, S., Emilio, A., Ruan, Q., et al. (2012). beta-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. EMBO Mol. Med. 4, 980–991. doi: 10.1002/emmm.201101084
Cavalari, M., Stamile, C., Umeton, R., Calimeri, F., and Orzi, F. (2015). Novel method for automated analysis of retinal images: results in subjects with hypertensive retinopathy and CADASIL. Biomed Res. Int. 2015:752957. doi: 10.1155/2015/752957
Cheung, C. Y., Ikram, M. K., Sabanayagam, C., and Wong, T. Y. (2012a). Retinal microvasculature as a model to study the manifestations of hypertension. Hypertension 60, 1094–1103. doi: 10.1161/HYPERTENSIONAHA.111.189142
Cheung, C. Y., Ong, Y. T., Hilal, S., Ikram, M. K., Low, S., Ong, Y. L., et al. (2015). Retinal ganglion cell analysis using high-definition optical coherence tomography in patients with mild cognitive impairment and Alzheimer’s disease. J. Alzheimers Dis. 45, 45–56. doi: 10.3233/JAD-141659
Cheung, C. Y., Ong, Y. T., Ikram, M. K., Ong, S. Y., Li, X., Hilal, S., et al. (2014). Microvascular network alterations in the retina of patients with Alzheimer’s disease. Alzheimers Dement. 10, 135–142. doi: 10.1016/j.jalz.2013.06.009
Cheung, C. Y., Thomas, G. N., Tay, W., Ikram, M. K., Hsu, W., Lee, M. L., et al. (2012b). Retinal vascular fractal dimension and its relationship with cardiovascular and ocular risk factors. Am. J. Ophthalmol. 154, 653.e1–674.e1. doi: 10.1016/j.ajo.2012.04.016
Cheung, N., Mosley, T., Islam, A., Kawasaki, R., Sharratt, A. R., Klein, R., et al. (2010). Retinal microvascular abnormalities and subclinical magnetic resonance imaging brain infarct: a prospective study. Brain 133(Pt 7), 1987–1993. doi: 10.1093/brain/awq127
Cheung, N., and Wong, T. Y. (2012). Predicting risk of diabetic retinopathy from retinal vessel analysis: personalized medicine in transition. Arch. Ophthalmol. 130, 783–784. doi: 10.1001/archophthalmol.2012.727
Cui, A., Simo-Servat, O., Hernandez, C., Arcos, G., Diego, S., Sanabria, A., et al. (2017). Retinal microperimetry: a new tool for identifying patients with type 2 diabetes at risk for developing Alzheimer disease. Diabetes Metab. Res. Rev. 31, 3098–3104. doi: 10.2337/db17-0382
Coppola, G., Di Renzo, A., Ziccardi, L., Martelli, F., Fadda, A., Manni, G., et al. (2015). Optical coherence tomography in Alzheimer’s disease: a meta-analysis. PLoS One 10:e0134750. doi: 10.1371/journal.pone.0134750
Cordeiro, M. F., Guo, L., Coxon, K. M., Duggan, J., Nizari, S., Normando, E. M., et al. (2010). Imaging multiple phases of neurodegeneration: a novel approach to assessing cell death in vivo. Cell Death Dis. 1:e3. doi: 10.1038/cddis.2009.3
Cordeiro, M. F., Guo, L., Luong, V., Harding, G., Wang, W., Jones, H. E., et al. (2004). Real-time imaging of single nerve cell apoptosis in retinal neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 101, 13352–13356. doi: 10.1073/pnas.040579101
Crowe, M. J., Bresnahan, J. C., Shuman, S. L., Masters, J. N., and Beattie, M. S. (1997). Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat. Med. 3, 73–76. doi: 10.1038/nm0197-73
Cisniski, L., MacGilivray, T. J., Flynn, E., Pellegrini, E., Papanastasiou, G., Barzagari-Befroz, E., et al. (2018). Peripheral retinal imaging biomarkers for Alzheimer’s disease: a pilot study. Ophthalmic Res. 59, 182–192. doi: 10.1159/000487053
Danesh-Meyer, H. V., Birch, H., Ku, J. Y., Carroll, S., and Gamble, G. (2006). Reduction of optic nerve fibers in patients with Alzheimer disease identified by laser imaging. Neurology 67, 1852–1854. doi: 10.1212/01.wnl.0000244490.07925.8b
Dinet, V., Bruban, J., Chalour, N., Maoui, A., An, N., Jonet, L., et al. (2012). Distinct effects of inflammation on gliosis, osmohomeostasis, and vascular integrity
during amyloid beta-induced retinal degeneration. Aging Cell 11, 683–693. doi: 10.1111/j.1474-9726.2012.00834.x

Ding, J., Strachan, M. W., Fowkes, F. G., Wong, T. Y., Macgillivray, T. J., Patton, N., et al. (2011). Association of retinal arterial dilatation with lower verbal memory: the Edinburgh type 2 diabetes study. Diabetologia 54, 1653–1662. doi: 10.1007/s00125-011-2129-1

Dong, J., Revilla-Sanchez, R., Moss, S., and Haydon, P. G. (2010). Multiphoton in vivo imaging of amyloid in animal models of Alzheimer's disease. Neuropharmacology 59, 268–275. doi: 10.1016/j.nephph.2010.04.007

Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., et al. (2014). Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370, 311–321. doi: 10.1056/NEJMoa1312889

Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., et al. (2014). Tau inclusions in retinal ganglion cells of human P301S tauopathy in Alzheimer's disease. Acta Ophthalmol. Scand. 92, 271–275. doi: 10.1111/j.1600-0420.1996.tb08300.x

Heringa, S. M., Bouvy, W. H., van den Berg, E., Moll, A. C., Kappelle, L. J., and Biessels, G. J. (2013). Associations between retinal microvascular changes and dementia, cognitive functioning, and brain imaging abnormalities: a systematic review. J. Cereb. Blood Flow Metab. 33, 983–995. doi: 10.1038/jcbfm.2013.58

Hintersteiner, M., Enz, A., Frey, P., Jaton, A. L., Kinzy, W., Kneuer, R., et al. (2005). In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazime derivative probe. Nat. Biotechnol. 23, 577–583. doi: 10.1038/nbt1085

Hinton, D. R., Sadun, A. A., Blanks, J. C., and Miller, C. A. (1986). Optic nerve degeneration in Alzheimer's disease. N. Engl. J. Med. 315, 485–487. doi: 10.1056/NEJM198608213150804

Ho, W. L., Leung, Y., Tsang, A. W., So, K. F., Chiu, K., and Chang, R. C. (2012). Review: tauopathy in the retina and optic nerve: does it shadow pathological changes in the brain? Mol. Vis. 18, 2700–2710.

Holtzman, D. M., Morris, J. C., and Goate, A. M. (2011). Alzheimer's disease: the challenge of the second century. Sci. Transl. Med. 3:77sr1. doi: 10.1126/scitranslmed.3002369

Huang, D., Swanson, E. A., Lin, C. P., Schuman, J. S., Stinson, W. G., Chang, W., et al. (1991). Optical coherence tomography. Science 254, 1178–1181. doi: 10.1126/science.1957169

Iseri, P. K., Alintas, O., Tokay, T., and Yuksel, N. (2006). Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J. Neuroophthalmol. 26, 18–24. doi: 10.1097/01.wno.0000204658.56873.26

Jahn, T. R., Makin, O. S., Marshall, K. E., Tian, P., Sikorski, P., et al. (2010). The common architecture of cross-beta amyloid. J. Mol. Biol. 395, 717–727. doi: 10.1016/j.jmb.2009.09.039

James, O. G., Dorsaiwamy, P. M., and Borges-Neto, S. (2015). PET imaging of tau pathology in Alzheimer's disease and tauopathies. Front. Neurof. 6:38. doi: 10.3389/fnins.2015.00038

Jellinger, K. A., and Attems, J. (2015). Challenges of multimorbidity of the aging brain: a critical update. J. Neurotransm. 122, 505–521. doi: 10.1007/s00702-014-1288-x

Kang, B. H., and Kim, J. I. (2013). Decreased retinal thickness in patients with Alzheimer's disease. J. Korean Neurol. Assoc. 31, 173–177.
Katz, B., Rimmer, S., Iragui, V., and Katzman, R. (1989). Abnormal pattern electroretinogram in Alzheimer's disease: evidence for retinal ganglion cell degeneration. *Ann. Neurol.* 26, 221–225. doi: 10.1002/ana.410260207

Kaur, C., Foulds, W. S., and Ling, E. A. (2008). Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. *Prog. Eye Res.* 27, 622–647. doi: 10.1016/j.preteyere.2008.09.003

Kergoat, H., Kergoat, M. J., Justino, L., Chertkov, H., Robillard, A., and Bergman, H. (2002). Visual retinocortical function in dementia of the Alzheimer type. *Gerontology* 48, 197–203. doi: 10.1159/000058350

Kernt, M., Iadi, I., Pinter, F., Seidensticker, F., Hirneiss, C., Hartlitoglu, C., et al. (2012). Assessment of diabetic retinopathy using nonmydriatic ultra-widefield scanning laser ophthalmoscopy (Optomap) compared with ETDRS 7-field stereo photography. *Diabetes Care* 35, 2459–2463. doi: 10.2337/dc12-0346

Kesler, A., Vakhapova, V., Korczyn, A. D., Naftali, E., and Neudorfer, M. (2011). Retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. *Clin. Neurosci. Neurosurg.* 113, 523–526. doi: 10.1016/j.clineuro.2011.02.014

Kim, D. H., Newman, A. B., Hajar, I., Strotmeyer, E. S., Klein, R., Newton, E., et al. (2011). Retinal microvascular signs and functional loss in older persons: the cardiovascular health study. *Stroke* 42, 1589–1595. doi: 10.1161/STROKEAHA.110.605261

Kirbas, S., Turkyilmaz, K., Anlar, O., Tufekci, A., and Durmus, M. (2013). Retinal nerve fiber layer thickness in patients with Alzheimer disease. *J. Neuroophthalmol.* 33, 58–61. doi: 10.1097/WNO.0b013e31828eddf5

Klaver, C. C., Ott, A., Hofman, A., Assink, J. J., Breteler, M. M., and de Jong, P. T. (1999). Age-related maculopathy associated with Alzheimer's Disease? The Rotterdam study. *Am. J. Epidemiol.* 150, 963–968. doi: 10.1093/oxfordjournals.aje.a010105

Koronyo, Y., Biggs, D., Barron, E., Boyer, D. S., Pearlman, J. A., Au, W. J., Kirbas, S., Turkyilmaz, K., Anlar, O., Tufekci, A., and Durmus, M. (2013). Retinal microvascular signs and functional loss in older persons: the cardiovascular health study. *Stroke* 42, 1589–1595. doi: 10.1161/STROKEAHA.110.605261

Koronyo-Hamaoui, M., Koronyo, Y., Salumbides, B. C., Black, K. L., and Koronyo-Hamaoui, M. (2012). Alzheimer's disease in the retina: imaging retinal abeta plaques for early diagnosis and therapy assessment. *Neurodegener. Dis.* 10, 285–293. doi: 10.1159/000335154

Koronyo-Hamaoui, M., Koronyo, Y., Ljubimov, A. V., Miller, K. M., Black, K. L., et al. (2011). Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. *Neuroimage* 54(Suppl. 1), S204–S217. doi: 10.1016/j.neuroimage.2010.06.020

Krasodomska, K., Lubinski, W., Potemkowski, A., and Honczarek, K. (2010). Pattern electroretinogram (PERG) and pattern visual evoked potential (PVEP) in the early stages of Alzheimer's disease. *Doc. Ophthalmol.* 121, 111–121. doi: 10.1007/s10633-010-9238-x

Kromer, R., Berbecic, N., Hauser, L., Froelich, L., Aboul-Enine, F., and Beutelspacher, S. C. (2014). Detection of retinal nerve fiber layer defects in Alzheimer's disease using SD-OCT. *Front. Psychiatry* 5:22. doi: 10.3389/fpsyt.2014.00022

Kromer, R., Serbecic, N., Hauser, L., Froelich, L., and Beutelspacher, S. C. (2013). Comparison of visual evoked potentials and retinal nerve fiber layer thickness in Alzheimer's disease. *Front. Neurol.* 4:203. doi: 10.3389/fneur.2013.00203

Kurna, S. A., Akar, A., Altun, A., Agirman, Y., Gozke, E., and Sengor, T. (2014). Confocal scanning laser tomography of the optic nerve head on the patients with Alzheimer's disease compared to glaucoma and control. *Int. Ophthalmol.* 34, 1203–1211. doi: 10.1007/s10792-014-0004-z

Leung, C. K., Cheung, C. Y., Weinreb, R. N., Qiu, Q., Liu, S., Li, H., et al. (2009). Retinal nerve fiber layer imaging with spectral-domain optical coherence tomography: a variability and diagnostic performance study. *Ophthalmology* 116, 1257–1263. doi: 10.1016/j.ophtha.2009.04.013

Levkovitch-Verbin, H., Quigley, H. A., Kerrigan-Baumrind, L. A., D'Anna, S. A., Kerrigan, D., and Pease, M. E. (2001). Optic nerve transection in monkeys may result in secondary degeneration of retinal ganglion cells. *Invest. Ophthalmol. Vis. Sci.* 42, 975–982.

Levkovitch-Verbin, H., Quigley, H. A., Martin, K. R., Zack, D. J., Pease, M. E., and Valenta, D. F. (2003). A model to study differences between primary and secondary degeneration of retinal ganglion cells in rats by partial optic nerve transection. *Invest. Ophthalmol. Vis. Sci.* 44, 3388–3393. doi: 10.1167/iovs.02-0646
Parisi, V., Restuccia, R., Fattapposta, F., Mina, C., Bucci, M. G., and Pierelli, F. (2003). Correlation between morphological and functional retinal impairment in Alzheimer's disease. *Alzheimers Dement.* 10, 340–345. doi: 10.1016/j.dadm.2018.03.002

Ong, Y. T., Hilal, S., Cheung, C. Y., Xu, X., Chen, C., Venkatasubramanian, N., et al. (2014). Retinal vascular fructals and cognitive impairment. *Dement. Geriatr. Cogn. Dis. Extra* 4, 305–313. doi: 10.1159/000363286

Paquet, C., Boissonnot, M., Roger, F., Dighiero, P., Gil, R., and Hugon, J. (2007). Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. *Neurosci. Lett.* 420, 97–99. doi: 10.1016/j.neulet.2007.02.090

Parisi, V. (2003). Correlation between morphological and functional retinal impairment in patients affected by ocular hypertension, glaucoma, demyelinating optic neuritis and Alzheimer's disease. *Semin. Ophthalmol.* 18, 50–57.

Parisi, V., Restuccia, R., Fattapposta, F., Mina, C., Bucci, M. G., and Pierelli, F. (2001). Morphological and functional retinal impairment in Alzheimer's disease patients. *Clin. Neurophysiol.* 112, 1860–1867. doi: 10.1016/S1388-2457(01)00620-4

Park, S. W., Kim, J. H., Mook-Jung, I., Park, W. J., Park, K. H., et al. (2014). Intracellular amyloid beta alters the tight junction of retinal pigment epithelium in 5XFAD mice. *Neurobiol. Aging* 35, 2013–2020. doi: 10.1016/j.neurobiaging.2014.03.008

Parnell, M., Guo, L., Abdi, M., and Cordeiro, M. F. (2012). Ocular manifestations of Alzheimer's disease in animal models. *Int. J. Alzheimers Dis.* 2012:786494. doi: 10.1155/2012/786494

Pase, M. P., Herbert, A., Grima, N. A., Pipingas, A., and O'Rourke, M. F. (2012). Retinopathy and risk of dementia: the Rotterdam study. *Neurology* 79, 365–370. doi: 10.1212/WNL.0b013e318260c7de

Schuman, S. G., Koreishi, A. F., Farsiu, S., Jung, S. H., Izatt, J. A., and Toth, C. A. (2009). Photoreceptor layer thinning over druse in eyes with age-related macular degeneration imaged in vivo with spectral-domain optical coherence tomography. *Optimaging* 116, 488.e–496.e. doi: 10.1016/j.opthima.2008.10.006

Schwartz, M., Belkin, M., Yoles, E., and Solomon, A. (1996). Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration. *J. Glaucoma* 5, 427–432. doi: 10.1006/jgsu.1996.00012

Sevgi, N., Chiao, P., Bussiere, T., Weinreb, P. H., Williams, L., Maier, M., et al. (2016). The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. *Nature* 537, 50–56. doi: 10.1038/nature19323

Siemers, E. R., Sundell, K., Carlson, C., Sethuraman, G., Liu-Seifert, H., et al. (2016). Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer’s disease patients. *Alzheimers Dement.* 12, 110–120. doi: 10.1016/j.alz.2015.10.003

Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., et al. (2011a). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 7, 280–292. doi: 10.1016/j.jalz.2011.03.003

Sperling, R. A., Jack, C. R. Jr., and Aisen, P. S. (2011b). Testing the right target and right drug at the right stage. *Sci. Transl. Med.* 3:111cm133. doi: 10.1126/scitranslmed.3002609

Stefansson, E., Olafsdottir, O. B., Einarsdottir, A. B., Eliassdottir, T. S., Eysteinsson, T., Vehmeijer, W., et al. (2017). Retinal oximetry discovers novel biomarkers in retinal and brain diseases. *Invest. Ophthalmol. Vis. Sci.* 58, BICO227–BICO233. doi: 10.1167/iovs.17-21776

Stenn, K., Dal-Bianco, P., Weghaupt, H., Koch, G., Vass, C., and Gottlob, I. (1991). Pattern electroretinogram and luminance electroretinogram in Alzheimer's disease. *J. Neural Transm. Suppl.* 33, 73–80. doi: 10.1007/978-3-7091-9135-4_12

Tan, O., Chopra, V., Lu, A. T., Schuman, J. S., Ishikawa, H., Wollstein, G., et al. (2009). Detection of macular ganglion cell loss in glaucoma by Fourier-domain optical coherence tomography. *Optimaging* 116, 2305.e2–2314.e2. doi: 10.1016/j.opthima.2009.05.025

Taylor, A. M., MacGillivray, T. J., Henderson, R. D., Ilizina, L., Dhillon, B., Starr, J. M., et al. (2015). Retinal vascular fractal dimension, childhood IQ, and
cognitive ability in old age: the Lothian Birth Cohort Study 1936. *PLoS One* 10:e0121119. doi: 10.1371/journal.pone.0121119

Terry, R. D., DeTeresa, R., and Hansen, L. A. (1987). Neocortical cell counts in normal human adult aging. *Ann. Neurol.* 21, 530–539. doi: 10.1002/ana.410210603

Thomson, K. L., Yeo, J. M., Waddell, B., Cameron, J. R., and Pal, S. (2015). A systematic review and meta-analysis of retinal nerve fiber layer change in dementia, using optical coherence tomography. *Alzheimers Dement.* 1, 136–143. doi: 10.1016/j.jalz.2015.03.001

Trick, G. L., Barris, M. C., and Bickler-Bluth, M. (1989). Abnormal pattern electroretinograms in patients with senile dementia of the Alzheimer type. *Ann. Neurol.* 26, 226–231. doi: 10.1002/ana.410260208

Tsai, C. S., Ritch, R., Schwartz, B., Lee, S. S., Miller, N. R., Chi, T., et al. (1991). Optic nerve head and nerve fiber layer in Alzheimer’s disease. *Arch. Ophthalmol.* 109, 199–204. doi: 10.1001/archoph.1991.01080020045040

Vecino, E., Rodriguez, F. D., Ruzafa, N., Pereiro, X., and Sharma, S. C. (2016). Glia-neuron interactions in the mammalian retina. *Prog. Retin. Eye Res.* 51, 1–40. doi: 10.1016/j.preteyeres.2015.06.003

Walton, O. B., Garoon, R. B., Weng, C. Y., Gross, J., Young, A. K., Camero, K. A., et al. (2016). Evaluation of automated teleretinal screening program for diabetic retinopathy. *JAMA Ophthalmol.* 134, 204–209. doi: 10.1001/jamaophthalmol.2015.5083

Wang, J., Ohno-Matsui, K., Yoshida, T., Shimada, N., Ichinose, S., Sato, T., et al. (2009). Amyloid-beta up-regulates complement factor B in retinal pigment epithelial cells through cytokines released from recruited macrophages/microglia: another mechanism of complement activation in age-related macular degeneration. *J. Cell. Physiol.* 220, 119–128. doi: 10.1002/jcp.21742

Williams, M. A., McGowan, A. J., Cardwell, C. R., Cheung, C. Y., Craig, D., Passmore, P., et al. (2015). Retinal microvascular network attenuation in Alzheimer’s disease. *Alzheimers Dement.* 1, 229–235. doi: 10.1016/j.jalz.2015.04.001

Williams, M. A., Silvestri, V., Craig, D., Passmore, A. P., and Silvestri, G. (2014). The prevalence of age-related macular degeneration in Alzheimer’s disease. *J. Alzheimers Dis.* 42, 909–914. doi: 10.3233/JAD-140243

Wu, Z., Aytin, L. N., Guymer, R. H., and Lou, C. D. (2014). Comparison between multifocal electroretinography and microperimetry in age-related macular degeneration. *Invest. Ophthalmol. Vis. Sci.* 55, 6431–6439. doi: 10.1167/iovs.14-14407

Yip, W., Siantar, R., Perera, S. A., Milastuti, N., Ho, K. K., Tan, B., et al. (2014). Reliability and determinants of retinal vessel oximetry measurements in healthy eyes. *Invest. Ophthalmol. Vis. Sci.* 55, 7104–7110. doi: 10.1167/iovs.13-13854

Yoles, E., and Schwartz, M. (1998). Degeneration of spared axons following partial white matter lesion: implications for optic nerve neuropathies. *Exp. Neurol.* 153, 1–7. doi: 10.1006/exnr.1998.6811

Zhang-Nunes, S. X., Maat-Schieman, M. L., van Duinen, S. G., Roos, R. A., Frosch, M. P., and Greenberg, S. M. (2006). The cerebral beta-amyloid angiopathies: hereditary and sporadic. *Brain Pathol.* 16, 30–39. doi: 10.1111/j.1750-3639.2006.tb00559.x

Zlokovic, B. V. (2011). Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. *Nat. Rev. Neurosci.* 12, 723–738. doi: 10.1038/nrn3114

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Liao, Zhu and Peng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.